Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.
FAQs
What is the price prediction for better therapeutics stock? ›
Better Therapeutics, Inc. stock prediction for 1 year from now: $ 0.100376 (1,124.10%) Better Therapeutics, Inc. stock forecast for 2025: $ 0.003784 (-52.71%) Better Therapeutics, Inc. stock prediction for 2030: $ 0.00008952 (-98.88%)
Is VRTX a buy sell or hold? ›Is Vertex Pharmaceuticals stock a Buy, Sell or Hold? Vertex Pharmaceuticals stock has received a consensus rating of buy. The average rating score is and is based on 62 buy ratings, 32 hold ratings, and 2 sell ratings.
Is BTTX stock a good buy? ›In the current month, BTTX has received 5 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings.
How high will VKTx go? ›VKTX Stock 12 Month Forecast
Based on 9 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $113.50 with a high forecast of $138.00 and a low forecast of $90.00.
Only one brokerage firm provided a Strong Buy-equivalent recommendation for Better Therapeutics, Inc. This translates to an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell).
Is amzn stock a buy? ›AMZN Analyst Recommendation Trends
In the current month, AMZN has received 79 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AMZN average Analyst price target in the past 3 months is $212.36.
CRISPR Therapeutics AG Stock Prediction 2025
The CRISPR Therapeutics AG stock prediction for 2025 is currently $ 74.58, assuming that CRISPR Therapeutics AG shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 34.02% increase in the CRSP stock price.
Shopify Inc.
may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of SHOP, demonstrate its potential to underperform the market. It currently has a Growth Score of A.
| Company Name | LTP | % Change |
|---|---|---|
| DIL | 8.3 | 1.84 |
| Kanani Industries | 3.9 | 0.00 |
| Dynamic Cables Ltd | 444.3 | -0.18 |
| Hilton Metal Forging | 116.5 | -0.77 |
Institutions that own VKTX
SSgA Funds Management, Inc. The Vanguard Group, Inc.
Why is VKTX a buy? ›
Its long-term growth potential looks like it's improving, again. Viking Therapeutics (VKTX -2.25%) is on a tear this year, with shares catapulting upward by 340% thanks to good data (and high expectations) from one of its mid-stage clinical trials testing a weight loss drug.
Is VRTX a strong buy? ›Vertex Pharmaceuticals Stock Forecast FAQ
Out of 14 analysts, 7 (50%) are recommending VRTX as a Strong Buy, 3 (21.43%) are recommending VRTX as a Buy, 3 (21.43%) are recommending VRTX as a Hold, 0 (0%) are recommending VRTX as a Sell, and 1 (7.14%) are recommending VRTX as a Strong Sell.
| High | $574.00 |
|---|---|
| Median | $450.00 |
| Low | $325.00 |
| Average | $464.96 |
| Current Price | $393.48 |
VTNR Stock Forecast FAQ
Vertex Energy has 65.13% upside potential, based on the analysts' average price target. Is VTNR a Buy, Sell or Hold? Vertex Energy has a conensus rating of Moderate Buy which is based on 2 buy ratings, 5 hold ratings and 0 sell ratings.
quote is equal to 0.225 USD at 2024-04-16. Based on our forecasts, a long-term increase is expected, the "VRTX" stock price prognosis for 2029-04-11 is 247.275 USD. With a 5-year investment, the revenue is expected to be around +109799.96%. Your current $100 investment may be up to $109899.96 in 2029.